BIOTESTLAB is participating in VIV Asia 2025, the largest exhibition of intensive livestock farming in Asia. This event, held every two years, took place from March 12 to 14 this year in Bangkok, Thailand's capital. It brought together 1,500 exhibitors, over 51,000 visitors from 129 countries, and more than 200 expert speakers who discussed key trends and innovations in the industry.
The BIOTESTLAB team showcased their research and production capabilities along with their product line. Currently, the company manufactures 130 medicinal products using 18 different technologies.
- different types of vaccines for poultry, cattle, pigs, rabbits;
- chemical and pharmaceutical drugs for productive and domestic animals;
- liquid feed additives;
- disinfectants and hygiene products.
Among the new products:
- inactivated vaccine Polimun ND EDS IB MAX (3 strains of IBV in the composition: Mass + 793/B + VAR2);
- injectable antibiotic Tulaxan (tulathromycin 10%);
- injectable antiparasitic agent Doran (doramectin 1%).
Andrii Sobko, the Executive Director Business Development, emphasized that the VIV Asia 2025 exhibition is a crucial international platform for BIOTESTLAB. It allows the company to establish new business connections and strengthen existing ones while offering valuable insights into development trends in the livestock industry. He remarked, “Our stand was busy with visitors throughout the exhibition, and we made over 50 new contacts for potential cooperation”.
Summing up the three days of VIV Asia 2025
1) Seven productive meetings with clients:
- an agreement has been reached regarding the product range in Thailand and the Philippines.
- the vaccine registration statuses in Vietnam, Sri Lanka, South Korea, and Pakistan have been updated.
- new targets have been set for Nepal for the current year.
2) Five meetings were held with previous contacts to discuss the terms of further work in Indonesia, Vietnam, Sri Lanka, South Korea, and Egypt.
3) Negotiations were held for more than ten contracts in India, Taiwan, Cambodia, Bangladesh, Malaysia, Laos, Turkey, Oman, Kuwait, and Sudan.
4) Thirteen meetings with vaccine manufacturers from seven countries were held to expand the range, joint production, and distribution.
Andrii Sobko noted, “Developing exports is one of our strategic priorities. This is our second time participating in VIV Asia. Events of this scale aim to strengthen the BIOTESTLAB brand’s position in the global market. It is gratifying to see that our company is becoming recognizable, and customers positively acknowledge the quality of our products”.
Currently, BIOTESTLAB is actively working on expanding its international presence by exporting products to 21 countries. Last year, we started supplying products to Bangladesh, and we are in ongoing negotiations with potential distributors in Southeast Asia, the Middle East, and North Africa. The primary focus is now the Sub-Saharan Africa region, while export opportunities to Latin America are also being explored. Besides B2B and B2G, the company is considering additional forms of cooperation, including joint developments, technology transfer, and contract manufacturing.
Calendar of upcoming events
- April 24-26 – VIV Turkey 2025 (Istanbul, Turkey);
- May 8-10 – International Poultry & Livestock Bangladesh Expo 2025 (Dhaka, Bangladesh).